Guardant Health, Inc. Common Stock (GH) Financials
Key financial figures for Guardant Health, Inc. Common Stock (Q3 2026).
Guardant Health's Q3 2026 revenue rose 36% to $361.0 million, led by Shield tests of 83,000 versus 24,000 a year earlier, and the company raised its full-year revenue guidance to $1.36 to $1.37 billion. Revenue was $361.0 million, up 36% from $265.2 million in Q3 2025. Oncology was $231.3 million (+25%) on 117,000 tests (+58%), Biopharma & Data was $59.0 million (+8%), and Screening was $67.6 million (+180%) on 83,000 Shield tests versus 24,000 a year earlier. GAAP gross margin was 65%, and non-GAAP gross margin was 67% versus 66% in Q3 2025. GAAP loss from operations widened to $132.8 million from $99.0 million; the release's non-GAAP reconciliation includes a $19.0 million "Other" adjustment in the quarter versus $0.5 million a year earlier. On the outlook: Full year 2026 revenue now $1.36 to $1.37 billion (growth of 38% to 40%), up from $1.34 to $1.36 billion. Oncology revenue growth of about 30% with volume growth over 50%; Biopharma & Data growth in the low double digits; Screening revenue $233 to $238 million on 285,000 to 290,000 Shield tests (prior $218 to $230 million on 270,000 to 285,000). Non-GAAP gross margin 65% (prior 64% to 65%); non-GAAP operating expenses $1.105 to $1.125 billion (prior $1.080 to $1.100 billion); free cash flow burn $205 to $220 million (prior $195 to $205 million). Figures are for Q3 2026, as Guardant Health Inc. reported them.
- Revenue
- $361M
- Net Income
- -$124M
- EPS
- $-0.93
- Total Assets
- $1.9B
- Operating Cash Flow
- -$24M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $361M | -$124M | -$0.93 | -36.78% | -$37M |
| Q2 FY2026 | $335M | -$120M | -$0.90 | -38.55% | -$70M |
| Q1 FY2026 | $302M | -$112M | -$0.85 | -40.23% | -$71M |
| Q4 FY2025 | $281M | -$128M | -$1.00 | -42.95% | -$54M |
| Q3 FY2025 | $265M | -$93M | -$0.74 | -37.33% | -$46M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $982M | -$416M | -$3.32 | -44.53% | -$233M |
| FY2024 | $739M | -$436M | -$3.56 | -60.02% | -$275M |
| FY2023 | $564M | -$479M | -$4.28 | -100.14% | -$345M |
Frequently asked questions
What was Guardant Health Inc.'s revenue last quarter?
Guardant Health Inc. reported revenue of $361.0 million for Q3 FY2026, up 36.1% from the same period a year earlier.
Is Guardant Health Inc. profitable?
Not in its most recent reported period. Guardant Health Inc. reported a net loss of $124.4 million for Q3 FY2026, a net margin of -34.45% on revenue.
How has Guardant Health Inc.'s margin trended?
Operating margin was -36.78% in Q3 FY2026, compared with -37.33% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Guardant Health Inc. generate?
Guardant Health Inc. generated free cash flow of -$37.2 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Guardant Health, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.